KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Receivables - Net: 2009-2025

Historic Receivables - Net for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $1.9 billion.

  • Vertex Pharmaceuticals' Receivables - Net rose 11.18% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 11.18%. This contributed to the annual value of $1.6 billion for FY2024, which is 2.94% up from last year.
  • Vertex Pharmaceuticals' Receivables - Net amounted to $1.9 billion in Q3 2025, which was up 2.79% from $1.9 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Receivables - Net peaked at $1.9 billion during Q3 2025, and registered a low of $929.1 million during Q2 2021.
  • Over the past 3 years, Vertex Pharmaceuticals' median Receivables - Net value was $1.7 billion (recorded in 2024), while the average stood at $1.7 billion.
  • Data for Vertex Pharmaceuticals' Receivables - Net shows a peak YoY soared of 43.45% (in 2022) over the last 5 years.
  • Over the past 5 years, Vertex Pharmaceuticals' Receivables - Net (Quarterly) stood at $1.1 billion in 2021, then climbed by 26.86% to $1.4 billion in 2022, then climbed by 8.40% to $1.6 billion in 2023, then climbed by 2.94% to $1.6 billion in 2024, then climbed by 11.18% to $1.9 billion in 2025.
  • Its Receivables - Net was $1.9 billion in Q3 2025, compared to $1.9 billion in Q2 2025 and $1.8 billion in Q1 2025.